Summit Therapeutics (SMMT) Stock Forecast & Price Target

$20.25 -0.44 (-2.15%)

As of 10:52 AM Eastern

Summit Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
1

Buy
9

Based on 10 Wall Street analysts who have issued ratings for Summit Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for SMMT.

Consensus Price Target

$34.11
68.48% Upside

According to the 10 analysts' twelve-month price targets for Summit Therapeutics, the average price target is $34.11. The highest price target for SMMT is $44.00, while the lowest price target for SMMT is $23.00. The average price target represents a forecasted upside of 68.48% from the current price of $20.25.

Get the Latest News and Ratings for SMMT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Summit Therapeutics and its competitors.

SMMT Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	9 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$34.11	$33.57	$33.33	N/A
Forecasted Upside	68.48% Upside	51.77% Upside	75.44% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	N/A

Remove Ads

SMMT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SMMT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Summit Therapeutics Stock vs. The Competition

Type	Summit Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	64.87% Upside	21,107.26% Upside	16.93% Upside
News Sentiment Rating	Positive News See Recent SMMT News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/21/2025	Cantor Fitzgerald 4 of 5 stars	Eric Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/12/2025	Evercore ISI 2 of 5 stars	Cory Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00	+62.16%
2/28/2025	The Goldman Sachs Group 3 of 5 stars	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00	+127.15%
2/25/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mitchell Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00	+133.55%
1/8/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Goonewardene Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00	+92.73%
12/11/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00	+66.94%
12/6/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$31.00	+76.94%
11/4/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$32.00	+68.51%
9/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$19.00 ➝ $23.00	+0.83%
9/25/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $40.00	+66.11%
Get the Latest News and Ratings for SMMT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:53 AM ET.

SMMT Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Summit Therapeutics is $34.11, with a high forecast of $44.00 and a low forecast of $23.00.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SMMT shares.
: According to analysts, Summit Therapeutics's stock has a predicted upside of 68.48% based on their 12-month stock forecasts.
: Summit Therapeutics has been rated by research analysts at Cantor Fitzgerald, Evercore ISI, HC Wainwright, The Goldman Sachs Group, and Truist Financial in the past 90 days.
: Analysts like Summit Therapeutics more than other "medical" companies. The consensus rating score for Summit Therapeutics is 2.90 while the average consensus rating score for "medical" companies is 2.82. Learn more on how SMMT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:SMMT) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Stock Forecast & Price Target